财务数据显示，截至2025年末，公司总资产预计达4.34亿元，较期初增长10.39%，主要源于生猪养殖业务的资产投入。但归属于上市公司股东的所有者权 益为2.65亿元，较期初下降9.81%；每股净资产降至2.39元。加权平均净资产收益率为-10.32%，较上年同期进一步下滑。 2月9日晚间，北交所上市公司山西大禹生物工程股份有限公司发布2025年度业绩快报。 报告期内，公司实现营业收入1.68亿元，同比增长36.78%；但归属于上市公司股东的净利润亏损2878.57万元，较上年同期亏损幅度扩大20.23%。这也是 公司自2023年以来第三年亏损。 业绩快报显示，大禹生物2025年营收增长主要得益于新拓展的生猪养殖业务。该板块全年贡献营收4218.97万元，成为公司收入增量的核心来源。然而， 正是这项新业务拖累了整体盈利能力。公司解释称，受生猪养殖行业周期性波动影响，2025年第四季度生猪市场价格大幅回落，导致养殖业务板块未能实 现盈利，直接造成公司净利润亏损较上年同期增加484.30万元。 除养殖业务亏损外，公司传统饲料添加剂、饲料及兽药等存量业务亦面临挑战。近年来，受行业产能调控和非洲猪瘟疫情影响，生猪养殖 ...

（文章来源：证券日报） 证券日报网讯 1月26日，大禹生物发布公告称，公司预计2025年归属于上市公司股东的净利润 为-3000.00万元至-2600.00万元，上年同期为-2394.27万元，变动比例-25.30%至-8.59%。 ...

证券日报网讯 1月14日，大禹生物发布公告称，公司2026年第一次临时股东会审议通过《关于部分募投 项目结项并将节余募集资金永久补充流动资金的议案》《关于预计2026年日常性关联交易的议案》《关 于2026年拟向银行、其他金融机构及融资租赁公司申请综合授信额度贷款的议案》等多项议案。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯 12月26日，大禹生物发布公告称，大禹生物第四届董事会第八次会议审议通过《关于部 分募投项目结项并将节余募集资金永久补充流动资金的议案》等多项议案。 ...

Core Insights - The animal health sector experienced a slight increase of 0.42% on December 19, with Huisheng Biological leading the gains [1] - The Shanghai Composite Index closed at 3890.45, up 0.36%, while the Shenzhen Component Index closed at 13140.22, up 0.66% [1] Stock Performance - Huisheng Biological (300871) closed at 20.75, with a rise of 2.47% and a trading volume of 45,200 shares, amounting to a transaction value of 92.96 million yuan [1] - Other notable performers included: - Qudongli (920275) at 9.27, up 2.43% [1] - Shenlian Biological (688098) at 9.01, up 2.15% [1] - Xianfeng Holdings (002141) at 3.74, up 1.91% [1] - Ruipu Biological (300119) at 19.60, up 1.87% [1] Capital Flow - The animal health sector saw a net outflow of 129 million yuan from institutional investors, while retail investors contributed a net inflow of 157 million yuan [2][3] - The detailed capital flow for selected stocks showed: - Xianfeng Holdings (002141) had a net inflow of 6.89 million yuan from institutional investors [3] - Ruipu Biological (300119) experienced a net outflow of 15.98 million yuan from institutional investors but a net inflow of 11.27 million yuan from retail investors [3] - Qudongli (920275) had a net inflow of 2.22 million yuan from retail investors [3]

猪肉板块高开，大禹生物、傲农生物涨超9%，东瑞股份、得利斯、正虹科技跟涨。 ...

Core Insights - The animal health sector experienced a decline of 0.24% on November 17, with Dayu Biological leading the drop [1] - The Shanghai Composite Index closed at 3972.03, down 0.46%, while the Shenzhen Component Index closed at 13202.0, down 0.11% [1] Stock Performance - Notable gainers included: - Qudongli (code: 920275) with a closing price of 10.68, up 5.12% [1] - *ST Lvkang (code: 002868) with a closing price of 42.57, up 5.01% [1] - Houfeng Holdings (code: 002141) with a closing price of 3.91, up 2.62% [1] - Major decliners included: - Dayu Biological (code: 920970) with a closing price of 8.70, down 3.87% [2] - Ruipu Biological (code: 300119) with a closing price of 20.61, down 2.92% [2] - Zhongmu Co., Ltd. (code: 600195) with a closing price of 7.94, down 1.98% [2] Capital Flow - The animal health sector saw a net outflow of 10.15 million yuan from institutional investors, while retail investors experienced a net outflow of 20.76 million yuan [2] - Conversely, speculative funds recorded a net inflow of 30.91 million yuan [2] Individual Stock Capital Flow - Notable capital flows included: - Biological Shares (code: 600201) with a net inflow of 12.08 million yuan from institutional investors [3] - Xianfeng Holdings (code: 002141) with a net inflow of 9.50 million yuan from institutional investors [3] - Ruipu Biological (code: 300119) with a net inflow of 1.05 million yuan from speculative funds [3] - Decliners in capital flow included: - *ST Lvkang (code: 002868) with a net outflow of 0.79 million yuan from institutional investors [3] - Hai Li Biological (code: 603718) with a net outflow of 2.82 million yuan from institutional investors [3]

Summary of Stock Buyback Activities on October 30 Core Insights - On October 30, a total of 26 companies announced 27 stock buyback-related updates, indicating a significant activity in the market [1] Group 1: New Buyback Proposals - 16 companies disclosed stock buyback proposals for the first time, with 6 companies proposing buyback amounts exceeding 10 million [1] - The highest proposed buyback amounts were from HeMai Co., Ltd. (up to 200 million), Sanli Shi (60 million), and Minsheng Health (50.544 million) [1] Group 2: Approved Buyback Plans - 2 companies had their buyback plans approved by shareholders, with the highest proposed amounts from Dayu Biological (up to 5.596 million) and New Weiling (20,200) [1] Group 3: Buyback Implementation Progress - 2 companies reported on the implementation of their buyback plans, with the highest amounts from Guyue Longshan (186 million) and Jiayi Co. (99.0246 million) [1] Group 4: Completed Buybacks - 5 companies completed buybacks exceeding 10 million, with the highest completed amounts from Huafa Co. (310 million), Shenzhou Digital (203 million), and Ruoyu Chen (200 million) [1] - As of October 30, a total of 1711 buyback plans have been completed this year, involving 1281 companies, with 330 companies completing buybacks exceeding 100 million [1] - The leading companies in completed buyback amounts include Kweichow Moutai (6 billion), Muyuan Foods (3 billion), and COSCO Shipping Holdings (2.146 billion) [1]

Core Viewpoint - The animal health sector experienced a decline of 0.36% on October 22, with Dayu Biological leading the drop. The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1]. Stock Performance Summary - The following stocks in the animal health sector showed varied performance: - Shengwu Co. (600201) closed at 10.78, up 0.56% with a trading volume of 327,000 shares and a turnover of 351 million yuan - Ruipu Biological (300119) closed at 21.50, up 0.51% with a trading volume of 73,200 shares and a turnover of 158 million yuan - Haili Biological (603718) closed at 7.04, up 0.28% with a trading volume of 44,200 shares and a turnover of 31.17 million yuan - Dayu Biological (920970) closed at 9.46, down 1.25% with a trading volume of 20,800 shares and a turnover of 19.89 million yuan - ST Lvkang (002868) closed at 28.49, down 1.18% with a trading volume of 9,904 shares and a turnover of 28.26 million yuan [1][2]. Capital Flow Analysis - The animal health sector saw a net outflow of 47.45 million yuan from institutional investors, while retail investors contributed a net inflow of 36.66 million yuan. Speculative funds recorded a net inflow of 10.80 million yuan [2][3]. - Specific stock capital flows included: - Shunlian Biological (688098) had a net inflow of 6.94 million yuan from institutional investors but a net outflow of 12.58 million yuan from retail investors - Ruipu Biological (300119) experienced a net outflow of 2.94 million yuan from institutional investors, with a significant net inflow of 13.74 million yuan from speculative funds [3].

Core Viewpoint - Dayu Biological is increasing its investment in pig farming despite ongoing pressure in the pig breeding industry, aiming to extend its industrial chain and stabilize its feed sales channels [2][4]. Company Summary - Dayu Biological's wholly-owned subsidiary, Shanxi Dayu Animal Husbandry Co., Ltd., plans to invest 50 million yuan in its other subsidiary, Puxian Dayu Smart Animal Husbandry Industry Development Co., Ltd., raising its registered capital from 30 million yuan to 80 million yuan [2]. - The company primarily focuses on the research, production, and sales of feed additives, feed, and veterinary drugs, and has faced performance fluctuations since its listing on the Beijing Stock Exchange in 2022, recording its first loss in 2023 [2]. - Financial data shows Dayu Biological's revenue for 2022, 2023, and 2024 was 157 million yuan, 161 million yuan, and 123 million yuan respectively, with net profits of 18.15 million yuan, -2.09 million yuan, and -23.94 million yuan [2]. Industry Summary - The pig farming industry is undergoing structural changes, with a trend towards large-scale operations replacing smallholder farms, impacting Dayu Biological's sales of feed and additives [3]. - The company is adopting a "company + farmer" model to address challenges from the changing structure of downstream farming, having established a fully-owned subsidiary for pig farming in 2024 with an investment of 100 million yuan [3]. - As of August 2025, the national breeding sow inventory reached 40.38 million heads, indicating high production capacity, while pig prices remain low, affecting the profitability of many listed pig companies [4].